Table 8.
Epitope-specific Serum IgE/(kappa + lambda) Titer Ratios
| Pre-Treatment Serum Tested 1-35 Weeks After Therapy Commencement | |||
|
| |||
| ADARM | HSYQE | KTGQF | |
|
| |||
| 1 Week: | 25 | 555k | 26 |
| 2 Weeks: | 818 | 400 | 1.7k |
| 4 Weeks: | 21 | 283 | 23 |
| 35 Weeks: | 6 | 130k | 0.2 |
|
| |||
| Serum Obtained and Tested 1-35 Weeks After Therapy Commencement | |||
|
| |||
| ADARM | HSYQE | KTGQF | |
|
| |||
| 1 Week: | Less than zero | Less than zero | Less than zero |
| 2 Weeks: | Less than zero | Less than zero | Less than zero |
| 4 Weeks: | Less than zero | Less than zero | Less than zero |
| 35 Weeks: | Less than zero | Less than zero | Less than zero |
The Table depicts a quantitative summary of Table sets 4, 5, 6, and 7, wherein the MS patient’s pretreatment serum sample was test-positive and corresponding post-treatment samples were test-negative.